Logo

Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

Apr 27, 2022

Illumina, Janssen Biotech Form Strategic Partnership to Develop Precision Medicines

Apr 13, 2022

SomaLogic Targeting Cardiovascular Risk Panel for Use as Surrogate Endpoint in Drug Development
Premium

Apr 7, 2022

UK Study Supports Clinical Adoption of Genedrive Newborn Hearing Loss Test Within NHS
Premium

Nov 10, 2021

Fulgent Genetics Details Diversification, Expansion Strategies
Premium

Sep 27, 2021

Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development

Aug 3, 2021

Sorrento Therapeutics, National Institute of Genomic Medicine of Mexico to Form SARS-CoV-2 Alliance

Jul 28, 2021

PathAI Leveraging Acquisition, $165M Financing to Expand Dx Business
Premium

Jun 15, 2021

Caris Life Sciences, Elevation Oncology Team on Targeted Drug Development

May 19, 2021

Tasso Gets CE Mark for At-Home Blood Collection Device

Apr 29, 2021

Burning Rock Biotech, Abbisko Therapeutics Ink CDx Partnership for ABSK091

Apr 15, 2021

Thermo Fisher Scientific to Acquire Contract Research Organization PPD for $17.4B

Dec 11, 2020

BTIG Initiates Coverage of NeoGenomics With Buy Rating

Nov 19, 2020

PMC Report Outlines Strong Growth, Future Challenges for Personalized Medicine Industry

Aug 28, 2020

Freenome Maintains CRC Early Detection Timeline as New Biomarker Discovery Studies Progress

Jul 28, 2020

Senate Republicans Propose $36B for HHS Coronavirus Testing, Drug Development

Jul 14, 2020

Merus, Caris Life Sciences Partner to ID NRG1 Fusion-Positive Cancer Patients for Clinical Trial

Jun 18, 2020

FDA Approves Epizyme's Tazverik, Roche CDx for EZH2-Mutated Follicular Lymphoma Patients

May 13, 2020

Adaptive Eyes NGS-Based Test for T Cell Response in COVID-19

Apr 15, 2020

Axovant, Invitae Launch Free Genetic Testing Program for Lysosomal Storage Diseases

Feb 20, 2020

FDA Releases List of Evidence-Based PGx Variants